Abstract
Introduction The PROTECT National Core Study was funded by the UK Health and Safety Executive (HSE) to investigate routes of transmission for SARS-CoV-2 and variation between settings.
Methods A workshop was organised in Oct 2022.We brought together evidence from five published epidemiological studies that compared risks of SARS-CoV-2 infection or COVID-19 mortality by occupation or sector funded by PROTECT relating to three non-overlapping data sets, plus additional unpublished analyses relating to the Omicron period. We extracted descriptive study level data and model results. We investigated risk across four pandemic waves using forest plots for key occupational groups by time-period.
Results Results were largely consistent across different studies with different expected biases. Healthcare and social care sectors saw elevated risks of SARS-CoV-2 infection and COVID-19 mortality early in the pandemic, but thereafter this declined and varied by specific occupational subgroup. The education sector saw sustained elevated risks of infection after the initial lockdown period with little evidence of elevated mortality.
Conclusions Increased in risk of infection and mortality were consistently observed for occupations in high risk sectors particularly during the early stage of the pandemic. The education sector showed a different pattern compared to the other high risk sectors, as relative risk of infections remained high in the later phased of the pandemic, although no increased in COVID-19 mortality (compared to low-risk occupations) was observed in this sector in any point during the pandemic.
Competing Interest Statement
All authors report funding from the UK Health and Safety Executive paid to their institution. SB reports funding to her institution from the Medical Research Council MR/N013867/1. AH serves on the UK New and Emerging Respiratory Virus Threats Advisory Group.
Funding Statement
This work was supported by funding through the National Core Study 'PROTECT' programme, managed by the Health and Safety Executive on behalf of HM Government. For work relating to Virus Watch: This work was supported by the Medical Research Council [Grant Ref: MC_PC 19070], awarded to UCL on 30 March 2020, and Medical Research Council [Grant Ref: MR/V028375/1], awarded on 17 August 2020. The study also received $15 000 of advertising credit from Facebook to support a pilot social media recruitment campaign on 18 August 2020. The antibody testing undertaken by the vaccine evaluation subcohort was supported by funding from the Department of Health and Social Care from February 2021 to March 2022.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
CIS received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195). All participants provided informed consent. For use of this data for this project statistics authority selfassessment classified the study as low risk. The ONS Research Accreditation Panel approved this assessment. The Hampstead NHS Health Research Authority Ethics Committee approved the Virus Watch study (20/HRA/2320), which and conformed to the ethical standards set out in the Declaration of Helsinki. All participants provided informed consent for all aspects of the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data may be obtained from a third party and are not publicly available. The data used in this study are available on the Office for National Statistics (ONS) Secure Research Service for Accredited researchers as the Public Health Research Database. Researchers can apply for accreditation through the Research Accreditation Service.
